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Abstract
Daptomycin non-susceptible Staphylococcus aureus was rarely encountered at our medical centre until 2010, when 10 isolates (0.4% of
S. aureus) were conﬁrmed by E-test as non-susceptible. These isolates were not of the same strain type and there was no link between the
10 patients. Daptomycin non-susceptibility may be increasing.
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Introduction
Daptomycin, a cyclic lipopeptide antibiotic, is a rapidly
bactericidal agent that is widely utilized for treatment of
Staphylococcus aureus infections [1]. Staphylococcus aureus
isolates with a MIC >1 mg/mL are termed non-susceptible
to daptomycin (DNSSA). Despite a near decade of increasing
use [2], rates of DNSSA have remained stable at <0.2% [2–4].
Daptomycin non-susceptibility is a complex phenomenon.
Though the precise mechanisms leading to its development
are under active investigation, resistance has been associated
withhigh inoculum infections, thickenedbacterial cellwalls, prior
vancomycin treatment and prolonged daptomycin therapy
[5–8]. Though the clinical relevance of daptomycin non-sus-
ceptibility is not always clear, it developed in six initially
susceptible isolates during an endocarditis treatment trial, and
this resistance was associated with treatment failure [9].
Our 808-bed medical centre’s microbiology laboratory
rarely encountered DNSSA (0–1 case/year) from 2003 to
2009, but in 2010 we identiﬁed and conﬁrmed by E-test 10
clinically signiﬁcant DNSSA isolates. We report the clinical and
microbiological aspects of these 10 cases.
Methods
Possible DNSSA were identiﬁed during 2010 by the clinical
microbiology laboratory using either E-test (AB Biodisk) or
Vitek-2 (BioMerieux). Our laboratory’s Vitek-2 susceptibility
testing for Staphylococcus aureus only included daptomycin in
the later part of 2010; prior to that clinicians needed to
request daptomycin E-testing on a case by case basis. Those
tentatively identiﬁed as DNSSA were sent for broth micro-
dilution (9 of 10 isolates) and repeat E-testing (Laboratory
Specialists, Inc, Westlake, OH, USA). The conﬁrmed DNSSA
were molecularly characterized by pulsed-ﬁeld gel electropho-
resis [10], spa typing as described by the European Network of
Laboratories for Sequence Based Typing of Microbial Patho-
gens (SeqNet [http://www.seqnet.org]), and multi-locus
sequence typing (MLST)[11]. All vancomycin and linezolid
susceptibility testing was by E-test.
A comprehensive chart review was carried out on all
conﬁrmed DNSSA to determine associated patient demo-
graphics, hospital course and microbiological outcomes.
Results
Thirteen of 2703 Staphylococcus aureus isolates from 2010
were tentatively identiﬁed by Vitek-2 or E-test at our
microbiology department as possible DNSSA; ten (77%) were
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conﬁrmed by E-test and/or broth microdilution at the
reference laboratory (Table 1). The ten conﬁrmed DNSSA
isolates represented 0.37% of all 2010 Staphylococcus aureus
isolates at our institution. The remaining three isolates,
incorrectly labelled as DNSSA in our laboratory, all had a
daptomycin MIC of 2 mg/mL by Vitek-2, which was not
conﬁrmed by either broth microdilution or E-test.
Nine of the 10 DNSSA isolates were available for molecular
characterization. As shown in Table 2, ﬁve of these were USA
300, two USA 600, one USA 500 and one USA 100. The two
USA 600 isolates were not of the same strain type; two of the
ﬁve USA 300 isolates exhibited the USA 300-0114 PFGE
pattern, while the others were distinct subtypes. There was no
epidemiological ‘link’ between the patients. They were hospi-
talized throughout the year, were not in close proximity within
the hospital, and had no common contacts, procedures or
surgeries.
The infections (Table 3) included four skin/soft tissue
infections, two native valve endocarditis cases, two spinal
osteomyelitis cases (one with epidural abscess), an abdominal
abscess and a case of respiratory S. aureus colonization. Eight
of the isolates were MRSA; two were MSSA. While eight of the
10 patients had signiﬁcant medical histories, two were
otherwise healthy (Table 3). Seven patients each had received
vancomycin or daptomycin previously, but two had never
received either agent. One of the patients who had not
received daptomycin or vancomycin lived with an MRSA
patient who had previously received daptomycin. Four
isolates had a vancomycin MIC of 2 mg/mL, while the other
six isolates were  1.5 mg/mL. All isolates were susceptible to
linezolid.
Three patients were receiving empirical daptomycin when
the DNSSA was conﬁrmed and were then switched to other
agents. A fourth patient, an immunocompetent woman who
had a large MRSA pyomyositis, continued to be treated with
daptomycin and was a clinical failure. Her infection resolved
after clindamycin therapy. Six patients did not receive
daptomycin during the hospital stay during which their DNSSA
was conﬁrmed. One patient died of a non-staphylococcal
infection (Clostridium difﬁcile), while all others on whom we
have follow-up data recovered from their staphylococcal
infection.
Discussion
DNSSA had been rarely isolated at our institution prior to
2010; this is in keeping with recent US data in which 99.9% of
S. aureus isolates were susceptible and no ‘daptomycin creep’
was observed [2]. This changed in 2010, when 10 DNSSA
were documented. One possible limitation of our study was
that S. aureus isolates were not routinely tested for daptomy-
cin susceptibility until mid-2010, but such ‘targeted’ testing did
identify ﬁve of 10 resistant isolates in the ﬁrst half of 2010.
Prior to 2010, we had found only no or one isolates per year
using the same ‘targeted’ testing. Our ‘cluster’ of DNSSA was
not of the same strain type, and there was no common link
between cases. Though overall rates of DNSSA were low
(0.37%), this report should serve to remind clinicians to check
daptomycin susceptibility on all clinical isolates from patients
for whom daptomycin therapy is planned. Some physicians are
in the habit of using daptomycin blindly for S. aureus under the
TABLE 1. Microbiological data
Patient
Daptomycin (mg/mL) E-test
Orlando
Health MIC
E-test,
conﬁrmation
Broth
microdilution
Vancomycin
(mg/mL)
Linezolid
(mg/mL)
1 4 (Vitek-2) 2 2 1 2
2 3 (E-test) 4 4 2 2
3 4 (Vitek-2) 4 4 2 2
4 3 (E-test) 4 2 1 2
5 4 (Vitek-2) 4 4 2 2
6 3 (E-test) 2 2 1 2
7 2 (E-test) 2 N/A 1.5 2
8 2 (E-test) 2 2 0.5 2
9 3 (Vitek-2) 3 2 1 4
10 2 (Vitek-2) 2 2 2 2
N/A, not available.
TABLE 2. Molecular characterization of S. aureus isolates
Case PFGE pattern MLST spa type
1 ND ND ND
2 USA600 45 t362
3 USA300 8 t1678
4 USA300 8 t008
5 USA300 8 t024
6 USA600 45 t004
7 USA300 8 t008
8 USA300 8 t1678
9 USA500 8 t064
10 USA100 5 t002
ND, not done; PFGE, pulsed ﬁeld gel electrophoresis; MLST, multi locus sequence
typing.
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assumption that all S. aureus isolates are susceptible, a
potentially hazardous practice. Indeed, one patient’s high
daptomycin MIC was ignored and the patient failed to respond
to daptomycin therapy.
Prior courses of daptomycin or vancomycin have been
correlated with an increased risk of DNSSA, and a vancomycin
MIC  2 mg/mL has been found in a high proportion of
DNSSA [1, 3, 12]. Two of our 10 patients had not previously
received either vancomycin or daptomycin, and only four
patients had a vancomycin MIC  2 mg/mL. Though MSSA
isolates are rarely daptomycin non-susceptible [4], two of ours
were (cases 6 and 8). While prior vancomycin or daptomycin
use or a higher vancomycin MIC may have utility as markers
for an enhanced risk of DNSSA, testing of all S. aureus isolates
is clearly necessary.
Given the rarity of DNSSA, its optimal treatment is not well
deﬁned. All of our patients’ staphylococcal infections eventu-
ally were cured using a variety of agents (Table 3), and all were
susceptible to linezolid. A patient who was treated with
daptomycin in spite of non-susceptibility eventually failed and
was ‘rescued’ with clindamycin. The clever pairing of dapto-
mycin plus an antistaphylococcal beta-lactam [13–15] was not
used in any of our patients, but might be a valuable option in
such patients.
Daptomycin remains an extremely useful antistaphylococcal
agent. Though non-susceptible strains of S. aureus are infre-
quent, they may occur occasionally even in patients without
known risk factors. Appropriate testing is needed to ensure
daptomycin can be used with conﬁdence.
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